Strategy

Pfizer’s broad pipeline and recent acquisitions have yet to translate into a coherent market narrative, contributing to investor uncertainty during a critical period of strategic transition.

Model N’s Michael Grosberg breaks down the accelerated complexity, policy disruption, and data gaps testing manufacturer market access and revenue management strategies.

Ken Banta and Andy Milligan explore how life sciences leaders can rebuild relevance, consistency, and trust in today's complex and cost-focused era of healthcare.

New studies from 23andMe suggest genetic variation may modestly influence GLP-1 weight-loss response and side effects.

In becoming the first CFO to be named HBA Woman of the Year, AstraZeneca's Aradhana Sarin highlights how financial leadership now sits at the center of innovation, access and strategic transformation.

The agentic model is emerging as a strategic tool to compress analysis timelines, coordinate cross-functional teams and surface competitive intelligence in real time.

Where PBMs fit into the new market access landscape, how pharma companies can respond and the questions that remain.

Analysis of U.S. drug pricing reform in 2026 highlights how the Inflation Reduction Act, Medicare drug price negotiation, and most-favored-nation pricing initiatives are reshaping pharmaceutical pricing, limiting patent-driven market exclusivity, accelerating generic and biosimilar competition, and driving strategic shifts in market access, pricing models, and innovation priorities across the biopharma industry.

In Part 2 of our podcast video episode with ZS CEO Pratap Khedkar, he breaks down pharma's need to move beyond AI pilots to scalable impact—and how companies can "go from informing to solving" while navigating trust, regulation, and a rapidly shifting patient dynamic.

Regulators are shifting antitrust scrutiny in healthcare from market share and pricing toward how vertically integrated systems shape patient flow, access, and competitive dynamics, signaling deeper oversight of ecosystem design, strategic intent, and cumulative market influence.

CMS’s 2026 requirement for manufacturers to submit “reasonable assumptions” alongside ASP data formalizes the role of estimation in drug pricing, increasing scrutiny on how ASP is constructed and shifting reporting toward greater transparency and accountability.

Inside Consano Bio’s bet on first-in-class nerve repair—and what it takes to lead an early-stage biotech through uncertainty.

Fresh off 2025, where the sectors delivered strong stock gains and selective financing momentum despite volatile markets, companies navigate policy headwinds, patent cliffs, and shifting global innovation dynamics, factors that favor strategically driven growth pursuits ahead.

Pharma companies choosing between Salesforce and Veeva’s CRM has larger implications than many expect.

The business and market models drugmakers must continually adapt to stay competitive as 2026 progresses.

Competitive simulation is a powerful exercise for leaders and their teams, enabling them to move from strategy to execution in a safe environment.

Merck’s decision to establish oncology as a standalone business unit reflects a strategic response to blockbuster concentration risk, lifecycle complexity, and intensifying competitive dynamics, as the company prepares for the anticipated loss of exclusivity of Keytruda and repositions organizational design as a lever for long-term value protection and growth.

In this video episode, Pratap Khedkar, PhD, CEO of ZS, joins the Pharm Exec Podcast to discuss three distinct industry trends and strategy shifts converging at the moment amid the backdrop of US-driven global policy change.

EVERSANA’s president of Patient Services discusses using technology to bring a personalized approach to change care.

Three key takeaways from the JPM industry reset offer clear clues to how biopharma companies—and leaders—must adapt to stand out and ultimately thrive in 2026.

Eli Lilly's $1.5 billion pre-launch inventory of orforglipron signals an aggressive manufacturing strategy aimed at avoiding supply shortages and capturing early share in the competitive obesity market.

From lessons in risk-taking—and building “from zero”—to career-defining pivots, Leonard Mazur, CEO of Citius Pharmaceuticals, reflects on 50-plus years in pharma.

Special Guest Op-Ed: What a decade of collaboration and shared effort reveals about the future of drug development.

The shifting landscape amid China's biotech rises presents both opportunities and geopolitical challenges for growth strategies.

Ken Banta and Andrew Hall share insights on leading through uncertainty—covering culture, capital, risk, and the regulatory headwinds influencing key decisions in drug development.